脓毒症住院患者外周动脉疾病患病率及相关结局
基于美国全国住院患者样本(2016-2020)的横断面分析,评估脓毒症住院患者中动脉粥样硬化性心血管疾病(ASCVD)的患病率及其与院内死亡和截肢的关联。脓毒症住院中9.5%合并外周动脉疾病(PAD),PAD与院内死亡风险升高18%及大截肢或经跖骨截肢风险增至4.36倍相关。联合ASCVD的脓毒症住院死亡风险最高(aHR 1.34),而PAD单独与截肢风险关联最强(aHR 5.03)。
要点
- 脓毒症住院中PAD患病率为9.5%(95%CI 9.3%-9.6%)。
- PAD与院内死亡风险升高18%(95%CI 1.17-1.20)及大截肢或经跖骨截肢风险增至4.36倍(95%CI 4.18-4.56)相关。
- 联合ASCVD的脓毒症住院院内死亡风险最高(aHR 1.34;95%CI 1.31-1.36)。
核心结论
- 脓毒症与ASCVD常见且与不良结局风险升高相关,PAD诊断见于9.5%的脓毒症住院并与院内死亡风险增加约25%相关,PAD与院内截肢风险升高相关,抗血栓治疗与PAD脓毒症住院患者院内截肢和死亡风险降低相关,医学优化可能改善脓毒症合并ASCVD患者的结局。
研究设计与样本
- 基于美国全国住院患者样本(2016-2020)的横断面分析,纳入主要诊断为脓毒症的成人住院(≥18岁),排除结局数据(院内死亡)和人口学数据(年龄、性别、种族/民族)缺失者,采用Cox回归调整人口学和合并症,并进行抗血栓治疗亚组分析。
- 估计住院总数174,776,160例(年龄均值±标准误50±0.2岁;44%男性;65%白人),其中5.5%(95%CI 5.5%-5.6%)主要诊断为脓毒症(年龄69±0.1岁;51%男性;70%白人)。
主要发现
- 脓毒症住院中9.5%(95%CI 9.3%-9.6%)有PAD次要诊断(年龄73±0.05岁;58%男性;73%白人)。
- PAD与院内死亡调整风险升高18%(95%CI 1.17-1.20)及大截肢或经跖骨截肢风险增至4.36倍(95%CI 4.18-4.56)相关。
- 联合ASCVD的脓毒症住院院内死亡风险最高(aHR 1.34;95%CI 1.31-1.36),高于单独CAD(aHR 1.25;95%CI 1.24-1.27)或单独PAD(aHR 1.23;95%CI 1.21-1.26)。
- PAD脓毒症住院患者院内大截肢或经跖骨截肢风险(aHR 5.03;95%CI 4.76-5.32)高于联合ASCVD者(aHR 3.89;95%CI 3.66-4.14);CAD与截肢无显著关联(aHR 1.05;95%CI 0.999-1.1)。
- 亚组分析显示ASCVD与抗血栓治疗存在显著交互作用,在接受抗血栓治疗者中,ASCVD与院内死亡(P < .001)和截肢(P < .05)的关联小于全样本中的关联。
关键数值与推荐
- 脓毒症住院中PAD患病率9.5%(95%CI 9.3%-9.6%)。
- 联合ASCVD院内死亡aHR 1.34(95%CI 1.31-1.36),单独CAD aHR 1.25(95%CI 1.24-1.27),单独PAD aHR 1.23(95%CI 1.21-1.26)。
- PAD截肢aHR 5.03(95%CI 4.76-5.32),联合ASCVD截肢aHR 3.89(95%CI 3.66-4.14),CAD截肢aHR 1.05(95%CI 0.999-1.1)。
临床怎么用
- 作者认为,抗血栓治疗作为ASCVD医学优化的基石,与PAD脓毒症住院患者院内截肢和死亡风险降低相关。
- 作者认为,医学优化可能改善脓毒症合并ASCVD患者的结局。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Sepsis is common, deadly, and exacerbated by comorbid conditions. Atherosclerotic cardiovascular disease (ASCVD), including coronary artery disease (CAD) and peripheral artery disease (PAD), are risk factors for sepsis with minimal data on the association between PAD and outcomes. We aimed to evaluate the prevalence of ASCVD and the association between ASCVD and in-patient mortality and limb outcomes among sepsis hospitalizations. METHODS: We generated ASCVD prevalence estimates among survey-weighted adult sepsis hospitalizations within the National Inpatient Sample (2016-2020). We included hospitalizations with a primary diagnosis of sepsis and excluded nonadult patients (<18 years), and those with missing outcome data (ie, in-hospital mortality) and demographic data (ie, age, sex, and race/ethnicity). Associations between ASCVD and in-hospital mortality and major or transmetatarsal amputation among sepsis hospitalizations were evaluated using Cox regression, adjusting for demographics (age, sex, race/ethnicity, and income) and comorbidities (diabetes mellitus, end-stage renal disease, cerebrovascular disease, and hypertension). Subgroup analyses were conducted to assess moderation of the association between ASCVD and outcomes by antithrombotic therapy. RESULTS: Of 174,776,160 estimated hospitalizations (age, mean ± standard error, 50 ± 0.2 years; 44% male; 65% White), 5.5% (5.5%-5.6%) had a primary diagnosis of sepsis (age 69 ± 0.1; 51% male; 70% White); of which, 9.5% (9.3%-9.6%) had a secondary diagnosis of PAD (age 73 ± 0.05; 58% male; 73% White). PAD was associated with 18% higher adjusted risk of in-hospital mortality (95% confidence interval [CI], 1.17-1.20) and 4.36 times the risk of major or transmetatarsal amputation (95% CI, 4.18-4.56). Sepsis hospitalizations with joint ASCVD had the highest risk of in-hospital mortality (adjusted hazard ratio [aHR], 1.34; 95% CI, 1.31-1.36) compared with those with CAD alone (aHR, 1.25; 95% CI, 1.24-1.27) or PAD alone (aHR, 1.23; 95% CI, 1.21-1.26). Yet patients with PAD who were hospitalized for sepsis had a higher risk of in-hospital major or transmetatarsal amputation (aHR, 5.03; 95% CI, 4.76-5.32) compared with those with joint ASCVD (aHR, 3.89; 95% CI, 3.66-4.14); CAD was expectedly not associated with amputation (aHR, 1.05; 95% CI, 0.999-1.1). Subgroup analyses revealed significant interactions between ASCVD and antithrombotic therapy, such that, among those taking antithrombic therapy, the associations between ASCVD and in-hospital mortality (P < .001) and amputation (P < .05) were smaller when compared with the associations examined in the whole sample. CONCLUSIONS: Sepsis and ASCVD are common and associated with a higher risk of adverse outcomes. PAD diagnosis occurred among 9.5% of sepsis hospitalizations and, mirroring CAD, increased the risk of in-hospital mortality by approximately 25%. Expectedly, PAD was associated with a higher risk of in-hospital amputation. Antithrombotic therapies, a staple of ASCVD medical optimization, reduced the risk of in-hospital amputation and mortality among patients with PAD hospitalized for sepsis. Medical optimization may improve outcomes in patients with sepsis and ASCVD.
引用
- Iyer S, Jarosinski MC, Kennedy JN, et al. Peripheral arterial disease prevalence among sepsis hospitalizations and associated outcomes. J Vasc Surg. 2025. PMID: 40319930. doi:10.1016/j.jvs.2025.04.058
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。